Related references
Note: Only part of the references are listed.Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer
Hyun-Kyung Woo et al.
LAB ON A CHIP (2019)
Multiparametric liquid biopsy analysis in metastatic prostate cancer
Emmanuelle Hodara et al.
JCI INSIGHT (2019)
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
Heini M. L. Kallio et al.
BRITISH JOURNAL OF CANCER (2018)
In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells
Amin El-Heliebi et al.
CLINICAL CHEMISTRY (2018)
Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer
Christof Bernemann et al.
EUROPEAN UROLOGY (2017)
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
Marzia Del Re et al.
EUROPEAN UROLOGY (2017)
CTC-mRNA (AR-V7) Analysis from Blood Samples-Impact of Blood Collection Tube and Storage Time
Alison W. S. Luk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
Tilman Todenhoefer et al.
JOURNAL OF UROLOGY (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer
Wendy Onstenk et al.
CANCER TREATMENT REVIEWS (2016)
Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
Liana B. Guedes et al.
CLINICAL CANCER RESEARCH (2016)
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
Jonathan Welti et al.
EUROPEAN UROLOGY (2016)
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
E. S. Antonarakis et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
Christine Henzler et al.
NATURE COMMUNICATIONS (2016)
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
Kristine M. Wadosky et al.
ONCOTARGET (2016)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2016)
Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies
Yafeng Ma et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
Duo Xu et al.
CANCER RESEARCH (2015)
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
Wendy Onstenk et al.
EUROPEAN UROLOGY (2015)
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Emmanuel S. Antonarakis et al.
JAMA ONCOLOGY (2015)
Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
Yuanyuan Qu et al.
SCIENTIFIC REPORTS (2015)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
Bo Cao et al.
ONCOTARGET (2014)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal
Siu Chiu Chan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Karen E. Knudsen et al.
CLINICAL CANCER RESEARCH (2009)
Share Paper
